SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells

Lianhua Piao; Takehiro Suzuki; Naoshi Dohmae; Yusuke Nakamura; Ryuji Hamamoto

doi:10.18632/oncotarget.4760

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Priority Research Papers:

SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells

Lianhua Piao, Takehiro Suzuki, Naoshi Dohmae, Yusuke Nakamura and Ryuji Hamamoto _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:16939-16950. https://doi.org/10.18632/oncotarget.4760

Metrics: PDF 2480 views | HTML 3258 views | ?

Abstract

Lianhua Piao1, Takehiro Suzuki2, Naoshi Dohmae2, Yusuke Nakamura1 and Ryuji Hamamoto1

1 Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA

2 Biomolecular Characterizaion Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan

Correspondence to:

Ryuji Hamamoto, email:

Keywords: SUV39H2, carcinogenesis, LSD1, non-histone protein methylation

Received: May 02, 2015 Accepted: June 26, 2015 Published: July 03, 2015

Abstract

LSD1 is a histone lysine demethylase, which is highly expressed in multiple types of human cancer. Although its roles in transcriptional regulation have been well-studied, functional regulation of LSD1 by post-translational modifications still remains unknown. Here, we demonstrate that the histone lysine methyltransferase SUV39H2 trimethylated LSD1 on lysine 322. Knockdown of SUV39H2 resulted in a decrease of LSD1 protein even though the mRNA levels were unchanged. SUV39H2-induced LSD1 methylation suppresses LSD1 polyubiquitination and subsequent degradation. In addition, we also observed indirect effect of SUV39H2 overexpression on LSD1-target genes. Our results reveal the regulatory mechanism of LSD1 protein through its lysine methylation by SUV39H2 in human cancer cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4760

Publication Alerts

Post-Publication Promotion

Priority Research Papers:

SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells

Abstract